Every 10-Q that Oscar Health, Inc. (OSCR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OSCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSCR filings page.
Oscar Health, Inc. reported strong improvement in results for the quarter ended June 30, 2026. Total revenue was 4,880,220 (in thousands), up from 2,863,945 a year earlier, and net income attributable to Oscar Health, Inc. was 361,808 (in thousands) compared with a loss of 228,361. For the first six months, revenue reached 9,527,414 (in thousands) and net income was 1,040,804.
Membership was about 3.0 million effectuated members as of June 30, 2026, approximately 46% higher than a year earlier. Operating cash flow rose to 4,711,325 (in thousands), supporting cash and cash equivalents of 4,075,612 and short-term investments of 4,479,906. Oscar also reports growing risk-adjustment payables and substantial balances due to CMS, extensive use of quota share and excess-of-loss reinsurance, and describes evolving ACA marketplace rules, subsidy changes, and new pharmaceutical tariffs that could influence future membership levels, premium dynamics, and medical cost trends.
Oscar Health, Inc. delivered sharply stronger results for the quarter ended March 31, 2026. Total revenue rose to $4.65 billion from $3.05 billion, driven by higher premiums as membership grew to about 3.17 million, up roughly 56% year over year.
Net income attributable to Oscar Health, Inc. increased to $679.0 million compared with $275.3 million a year earlier. Diluted earnings per share improved to $2.07 from $0.92. The medical loss ratio improved to 70.5% from 75.4%, reflecting disciplined pricing, favorable claims development, and risk‑adjustment dynamics.
Selling, general, and administrative expenses rose with growth, but the SG&A expense ratio edged down to 15.2%. Cash and cash equivalents increased to $4.81 billion, and total assets reached $9.29 billion. Management highlights regulatory changes, risk‑adjustment uncertainty, and potential new drug‑related tariffs as key external factors that could influence future medical costs and membership.
Oscar Health (OSCR) reported a Q3 2025 net loss and higher revenue. Total revenue was $2,985,984 thousand, up from $2,423,482 thousand a year ago, driven by premium growth and investment income. Net loss attributable to the company was $137,450 thousand, or $0.53 per diluted share, compared with a $54,596 thousand loss in Q3 2024.
Cash and cash equivalents were $2,148,865 thousand, and long‑term debt rose to $686,294 thousand, reflecting the issuance of $410,000 thousand 2.25% convertible senior subordinated notes due 2030 and existing 7.25% notes due 2031. The company recorded risk adjustment transfer payable of $1,771,305 thousand as of September 30, 2025, after increasing estimates based on updated market data.
Oscar ended the quarter with approximately 2.1 million effectuated members and closed acquisitions of INSXCloud, IHC Specialty Benefits, and Healthinsurance.org in May 2025. Subsequent events included note conversions and exchanges, and the purchase of capped calls for $34,440 thousand to mitigate conversion-related dilution on the 2030 notes.